SCHEMBL20177256

SCHEMBL20177256

C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)nc3)c3c(N)ncnc32)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 1.00
BLK P51451 2/20 0.78
EGFR P00533 4/20 0.76
TEC P42680 3/20 0.76
BMX P51813 3/20 0.76
TXK P42681 2/20 0.76
LYN P07948 2/20 0.76
FGFR2 P21802 2/20 0.76
ITK Q08881 2/20 0.76
RIPK2 O43353 1/20 0.76
NR1I2 O75469 1/20 0.76
SLC22A3 O75751 1/20 0.76
LATS1 O95835 1/20 0.76
NUDT14 O95848 1/20 0.76
ABL1 P00519 1/20 0.76
ERBB2 P04626 1/20 0.76
LCK P06239 1/20 0.76
FYN P06241 1/20 0.76
PGR P06401 1/20 0.76
CSF1R P07333 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21330628 1.00 BTK (1.00) BTKBLKEGFRTECBMX
SCHEMBL20177281 0.95 BTK (0.91) BTKBLKEGFRTECBMX
SCHEMBL21338838 0.95 BTK (0.91) BTKBLKEGFRTECBMX
SCHEMBL21330630 0.95 BTK (0.91) BTKBLKEGFRTECBMX
SCHEMBL20144255 0.95 BTK (0.91) BTKBLKEGFRTECBMX
SCHEMBL200392 0.91 BTK (1.00) BTKBLKEGFRTECBMX
SCHEMBL200391 0.91 BTK (1.00) BTKBLKEGFRTECBMX
SCHEMBL201548 0.91 BTK (1.00) BTKBLKEGFRTECBMX
SCHEMBL21330649 0.89 BTK (1.00) BTKBLKEGFRFGFR2ITK
SCHEMBL20177254 0.89 BTK (1.00) BTKBLKEGFRFGFR2ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543239-B1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF HANGZHOU HEALZEN THERAPEUTICS CO LTD (CN) 2024-11-13 EP disclosed
US-10711006-B2 Selective Bruton's tyrosine kinase inhibitor and use thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) 2020-07-14 US disclosed
US-10711006-B2 Selective Bruton's tyrosine kinase inhibitor and use thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) 2020-07-14 US disclosed
EP-3543239-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
EP-3543239-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
US-20190276461-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2019-09-12 US disclosed
US-20190276461-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2019-09-12 US disclosed
WO-2018090792-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF 杭州和正医药有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276461-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF BTK, BMX, KCNK10 BTK 1/4885BLK 12/4885EGFR 467/4885
US-10711006-B2 Selective Bruton's tyrosine kinase inhibitor and use thereof BTK, SYK, LYN BTK 1/4885BLK 35/4885EGFR 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.